LLY Lilly (Eli)

Q2 2025 10-Q

Filed: Aug 7, 2025Period ending Jun 30, 2025

Health Care

Pharmaceutical PreparationsSEC EDGAR

Lilly (Eli) (LLY) 10-Q quarterly report for Q2 2025, filed with SEC EDGAR on Aug 7, 2025 for the fiscal period ending Jun 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q2 2025 10-Q

Management Discussion & Analysis

• Cash and cash equivalents $3.38B as of June 30, 2025, up from $3.27B Dec 31, 2024
• Total debt $39.90B, increased $6.26B from $33.64B at Dec 31, 2024, driven by $6.50B fixed-rate notes issuance

+3 more insights

Risk Factors

• Newly added risk: Collaboration amendment with Boehringer Ingelheim triggered one-time $370M Jardiance revenue benefit, affecting future revenue recognition
• Most materially updated risk: Increased R&D expenses by 23% QoQ driven by expanded early and late-stage portfolio investments

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$15.6B

Net Income

$5.7B

Net Margin

36.4%

Source: XBRL data from Lilly (Eli) Q2 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Lilly (Eli) Quarterly Reports

Q3 2025 10-Q

Q1 2025 10-Q

Get deeper insights on Lilly (Eli)

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.